<DOC>
	<DOCNO>NCT00481767</DOCNO>
	<brief_summary>Infection human papillomavirus ( HPV ) clearly establish central cause cervical cancer . The current study design assess immunogenicity safety GlaxoSmithKline Biologicals ' HPV vaccine 580299 female subject age 10-25 year enrol Africa . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Immunogenicity Safety GlaxoSmithKline Biologicals ' HPV Vaccine 580299 Healthy Females 10 - 25 Years Age .</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe and/or parents/legally acceptable representative comply requirement protocol enrol study . A female , include , 10 25 year age time first vaccination . Written oral , sign thumb print witness informed consent obtain subject prior enrolment . For subject legal age consent , write oral , sign thumb print witness informed consent obtain subject 's parent legally acceptable representative . In addition , write oral , sign thumb print witness informed assent must obtain subject . Free obvious health problem establish medical history , clinical examination laboratory test enter study . Subjects must negative urine pregnancy test screen visit Visit 1 ( Day 0 ) . Subjects must seronegative human immunodeficiency virus ( HIV ) screen visit . Subjects must nonchildbearing potential , , childbearing potential , must abstinent use adequate contraceptive precaution 30 day prior vaccination , negative pregnancy test must agree continue precaution two month completion vaccination series . Subjects reach menarche study therefore childbearing potential must agree follow precaution . Subjects must 6 sexual partner prior enrolment . Subjects must willing undergo HIV voluntary counsel test must willing informed HIV status . Subjects legal age consent must also willing parent legally acceptable representative inform HIV status . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period ( Month 12 ) . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose plan administration study period . Administration vaccine foreseen study protocol within 30 day first dose vaccine . Enrolment defer subject outside specify window . Planned administration vaccine foreseen study protocol within 30 day 30 day dose study vaccine . Previous vaccination HPV , plan administration HPV vaccine foreseen study protocol study period . Previous administration component investigational vaccine Cancer autoimmune disease treatment . Any confirm suspected immunosuppressive immunodeficient condition , include HIV infection base laboratory test perform screen visit . Hypersensitivity latex History allergic disease reaction likely exacerbate component vaccine/control . Acute disease time enrolment . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory test perform screen visit . History neurologic disorder seizure . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Pregnant breastfeed female . A woman plan become pregnant , likely become pregnant planning discontinue contraceptive precaution study period , two month last vaccine dose . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) .</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cervical cancer ;</keyword>
	<keyword>Human papillomavirus ( HPV ) vaccine</keyword>
	<keyword>HPV ;</keyword>
	<keyword>Papillomavirus ;</keyword>
</DOC>